Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19517
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDa Gama Duarte, Jessica-
dc.contributor.authorPeyper, Janique M-
dc.contributor.authorBlackburn, Jonathan M-
dc.date2018-09-03-
dc.date.accessioned2018-09-25T23:00:20Z-
dc.date.available2018-09-25T23:00:20Z-
dc.date.issued2018-12-
dc.identifier.citationMammalian genome : official journal of the International Mammalian Genome Society 2018; 29(11-12): 790-805-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19517-
dc.description.abstractRecent developments in the immuno-oncology field strongly support a role for the immune system in both the prevention and progression of melanoma. Melanoma is a highly immunogenic cancer, including its ability to induce tumour antigen-specific B cell and antibody responses through largely unknown mechanisms. This review considers likely hypothetical mechanisms by which anti-tumour surveillance detects pre-cancerous cells and by which immune (including B cell and antibody) responses may be elicited during malignancy. The review further considers potential pro- and anti-tumour functions of B cells and antibodies (including tertiary lymphoid structures) in both the tumour microenvironment and in circulation. Although the vast majority of studies have focused on T cells, recent evidence highlights the important roles of B cells in response to malignancy. B cells and antibodies are also discussed in the context of their potential utility as clinical biomarkers for various applications (as diagnostic, prognostic, therapeutic efficacy, and toxicity proxies), with a particular focus on protein microarray-based antibody detection and quantitation. Although the role of B cells in melanoma is incompletely understood, the measurement of circulating tumour-specific antibodies represents a promising avenue in the search for melanoma-relevant biomarkers.-
dc.language.isoeng-
dc.titleB cells and antibody production in melanoma.-
dc.typeJournal Article-
dc.identifier.journaltitleMammalian genome : official journal of the International Mammalian Genome Society-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Australia-
dc.identifier.affiliationDepartment of Integrative Biomedical Sciences & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa-
dc.identifier.doi10.1007/s00335-018-9778-z-
dc.identifier.orcid0000-0003-4289-5204-
dc.identifier.orcid0000-0001-5992-2470-
dc.identifier.orcid0000-0001-8988-9595-
dc.identifier.pubmedid30178304-
dc.type.austinJournal Article-
dc.type.austinReview-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Mar 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.